GIS Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes medicines for virology, oncology and other therapeutic areas in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Gilead Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$104.56 |
| 52 Week High | US$111.84 |
| 52 Week Low | US$57.29 |
| Beta | 0.24 |
| 1 Month Change | 13.23% |
| 3 Month Change | 20.09% |
| 1 Year Change | 52.51% |
| 3 Year Change | 96.73% |
| 5 Year Change | 34.19% |
| Change since IPO | 7,327.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| GIS | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.1% | -1.2% | -1.6% |
| 1Y | 52.5% | -13.4% | 13.8% |
Return vs Industry: GIS exceeded the German Biotechs industry which returned -13.4% over the past year.
Return vs Market: GIS exceeded the German Market which returned 13.8% over the past year.
Price Volatility
| GIS volatility | |
|---|---|
| GIS Average Weekly Movement | 4.0% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: GIS has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: GIS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 17,600 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for virology, oncology and other therapeutic areas in the United States, Europe, and internationally. The company offers Biktarvy, Genvoya, Descovy, Odefsey, Complera/Eviplera, Symtuza, Truvada, Stribild, and Sunlenca products for the treatment of HIV-1 infection; Veklury, an injection for intravenous use for the treatment of COVID-19; and Epclusa, Vemlidy, Harvoni, Viread, and Livdelzi for the treatment of liver disease. It also provides Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
Gilead Sciences, Inc. Fundamentals Summary
| GIS fundamental statistics | |
|---|---|
| Market cap | €130.70b |
| Earnings (TTM) | €441.94m |
| Revenue (TTM) | €26.47b |
295.7x
P/E Ratio4.9x
P/S RatioIs GIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GIS income statement (TTM) | |
|---|---|
| Revenue | US$28.75b |
| Cost of Revenue | US$6.25b |
| Gross Profit | US$22.50b |
| Other Expenses | US$22.02b |
| Earnings | US$480.00m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 24, 2025
| Earnings per share (EPS) | 0.39 |
| Gross Margin | 78.26% |
| Net Profit Margin | 1.67% |
| Debt/Equity Ratio | 138.8% |
How did GIS perform over the long term?
See historical performance and comparisonDividends
2.8%
Current Dividend Yield800%
Payout RatioDoes GIS pay a reliable dividends?
See GIS dividend history and benchmarks| Gilead Sciences dividend dates | |
|---|---|
| Ex Dividend Date | Mar 14 2025 |
| Dividend Pay Date | Mar 28 2025 |
| Days until Ex dividend | 0 days |
| Days until Dividend pay date | 14 days |
Does GIS pay a reliable dividends?
See GIS dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/13 20:27 |
| End of Day Share Price | 2025/03/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gilead Sciences, Inc. is covered by 69 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |